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Abstract
In the fecal immunological test, a suitable cut-off value may be selected to classify results as
either positive or negative. Our aim is to estimate the optimal cut-off value for detecting colo-
rectal cancer in different age and sex groups. This is a multicentric retrospective cohort
study of participants in CRC screening programs with FIT between 2006 and 2012. A total
of 545,505 participations were analyzed. Cancers diagnosed outside of the program were
identified after a negative test result (IC_test) up until 2014. The Wilcoxon test was used to
compare fecal hemoglobin levels. ROC curves were used to identify the optimal cut-off
value for each age and sex group. Screening program results were estimated for different
cut-off values. The results show that the Hb concentration was higher in colorectal cancer
(average = 179.6μg/g) vs. false positives (average = 55.2μg/g), in IC_test (average = 3.1μg/
g) vs. true negatives (average = 0μg/g), and in men (average = 166.2μg/g) vs. women (aver-
age = 140.2μg/g) with colorectal cancer. The optimal cut-off values for women were 18.3μg/
g (50-59y) and 14.6μg/g (60-69y), and 16.8μg/g (50-59y) and 19.9μg/g (60-69y) for men.
Using different cut-off values for each age and sex group lead to a decrease in the IC_test
rate compared to the 20μg/g cut-off value (from 0.40‰ to 0.37‰) and an increase in the
false positive rate (from 6.45% to 6.99%). Moreover, test sensitivity improved (90.7%),
especially in men and women aged 50-59y (89.4%; 90%) and women aged 60-69y (90.2%).
In conclusion, the optimal cut-off value varies for different sex and age groups and the use
of an optimal cut-off value for each group improves sensitivity and leads to a small decrease
in IC_tests, but also to a larger increase in false positives.
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Introduction
Colorectal cancer screening programs (CRCSP) are currently the main strategy for the early
detection of colorectal cancer (CRC). The purpose of these programs is to detect early-stage
CRC and adenoma, which are precursor lesions of CRC. A fecal occult blood test carried out
every two years, followed by a colonoscopy to confirm the diagnosis, is one of the strategies
recommended in the European guidelines for quality assurance in colorectal cancer screening
[1]. Also, the strategy is cost-effective compared to no screening [2].
Fecal occult blood tests measure human hemoglobin (Hb) concentration in feces. There are
two methods: guaiac and immunochemical (FIT). The FIT allows for automated reading and
the selection of cut-off values to classify results as positive or negative.
Screening with the guaiac test has shown to reduce CRC mortality by 15% [3], while screen-
ing with the FIT using a cut-off value of 20μg/g of feces has shown to reduce CRC by 22% com-
pared to the non-screened population [4]. Furthermore, the FIT has proven to be more
effective in detecting advanced neoplasia and is also more widely accepted by the population
[5–7].
In Spain, CRCSPs depend on the healthcare services of the various regions. The FIT with a
cut-off value of 20μg/g (100ng/ml) is the screening test currently used.
Population distribution by age and sex is a factor that influences the impact of CRCSPs
because CRC incidence and mortality is lower in women than in men, and tends to increase
with age. Worldwide cancer incidence in 2018 was estimated at 20.9 per 100,000 women and
30.3 per 100,000 men [8].
Differences in CRC incidence can be seen in screening results, specifically in the positive
test rate or the positive predictive value (PPV). A study describing the results of CRCSPs in
Spain found that the rate of positive tests and PPVs is higher in men than women [9]. Salas
et al. (2014) showed that a lower number of lesions (adenoma, CRC) are detected in women,
and particularly in the younger group of women aged 50–59 years [10]. A study showed that
when a cut-off value of 10μg/g is used for the entire population, the rate of positive tests con-
tinues to be higher in men [11].
Most studies evaluating the quality of CRCSP based on FIT use a single cut-off point for the
entire target population [12–16]. A study found that cut-off points above 25μg / g hardly affects
the positive predictive value of the test [12]. Chen et al. (2007) found that FIT sensitivity and
specificity varied for different age and sex groups with the same cut-off value, concluding that
a cost-effective cut-off value was 110ng/ml [14]. One study estimates variations in program
results when different cut-off values are used, showing the differences in the results by age and
sex [15]. Among the studies to determine the optimal FIT cut-off value, the results of a Japa-
nese study concluded that the optimal cut-off value was estimated at 200ng/ml [13]. Further-
more, a Spanish study estimated the optimal cut-off value for detecting CRC at 115ng/ml [16].
Studies showing that the amount of Hb in feces is different in men and women [17], in
addition to the differences found in CRCSP results by age and sex, have led several authors to
conclude that these two factors must be present in order to predict the probability of a lesion
in the colon or rectum [18–20]. Kim et al. (2016) also suggest that factors such as smoking and
exercise must be considered in addition to age and sex to determine the probability of CRC
[19]. A study suggests that using risk-adapted cut-off values may help to achieve targeted levels
of PPV [21]. A number of studies analyzing the results of CRCSPs that use the FIT conclude
that cut-off values for this test must be personalized by age and sex to improve program results
[18–22].
The purpose of this study was to identify sex- and age-specific FIT cut-off values and evalu-
ate CRCSP results for different cut-off values and by age and sex groups, thereby providing
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information for CRCSPs on FIT use that is personalized in accordance with these factors. The
analysis of a large population of CRCSP participants allows us to offer populational results for
Spain.
Materials and methods
The CRIBEA-CIN project is a multicentric retrospective cohort study of participants in
CRCSPs carried out in the Valencian Community, Region of Murcia, Canary Islands, and the
Basque Country (all located in Spain). The characteristics of these programs can be seen in the
study of Vanaclocha-Espi et al., 2017 [23]. This project was born with the aim of studying the
balance between predictive indicators of the benefits and adverse effects of CRCSPs.
This study was approved (May 29th, 2015) by the Clinical Research Ethics Committee
(CEIC) of the General Directorate of Public Health (DGSP) and the Advanced Public Health
Research Centre (CSIP) of the Valencian Community (Reference: PI15/02108). Taking into
account the project design, its large sample size and that the data are anonymized, the ethics
committee approved carrying out the study without requesting individualized consent from
each subject, following the regulations of the Declaration of Helsinki currently in effect (Octo-
ber 2008, Seoul).
The project analyzed information from all participations of the cohort of men and women
aged 50–69 invited to take part in the CRCSPs from 2006 until December 2012. In total,
558,629 FIT were carried out. Interval cancers were identified in this population up until 2014
through with Cancer registries and using an internationally defined protocol [24]. Identified
interval cancers either had a negative FIT result the last time they participated in the program
and were diagnosed within 0–24 months or longer in the event that the following invitation
was delayed, or had a positive FIT result and a negative CRC result after undergoing a colonos-
copy and were diagnosed in the follow-up period before the next invitation. The data were
obtained from the information systems of each of the participating CRCSPs in an anonymized
way and were combined in a common database.
This study analyzed data from participations with FIT and excluded any participations with
an unknown value in the qualitative test result (n = 13.124). The final sample used in this study
was made up of 545,505 participations with FIT.
Over the study period, the participating CRCSPs used FITs from different manufacturers.
For this study, the test results were standardized to μg/g of feces in order to make them
comparable.
The CRCSPs participating in this study used a cut-off value of 20μg/g of feces. An Hb con-
centration in feces of>20μg/g was considered a positive result requiring colonoscopy follow-
up in the Valencian Community, the Region of Murcia, and the Canary Islands, while a con-
centration of�20μg/g was considered positive in the Basque Country.
The population that completes the screening process receives one of 5 possible results (Fig 1):
• True negative (TN): patients with a negative FIT result who do not have a diagnosis of CRC
in the period between two invitations.
• False negative or FIT interval cancer (IC_test): patients diagnosed with CRC, although the
FIT gave a negative result. These cases of CRC are diagnosed after a negative screening pro-
cess and before the following invitation.
• True positive or screening cancer (SC): patients that have CRC and got a positive FIT result.
• False Positive (FP): patients that through colonoscopy are confirmed to not have CRC after a
positive FIT result. Adenomas are included in this group. Patients with Adenomas detected
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are included in colonoscopy surveillance every 3 or 5 years. And the rest of the patients are
incorporated into biannual FIT screening after 5 years.
• Colonoscopy IC (CI_colono): patients that got a positive FIT result and a normal result or
an adenoma diagnosis in the colonoscopy, but are diagnosed with CRC before the next pro-
gram test.
Statistical analysis
A descriptive analysis was carried out using boxplots of Hb concentration in feces from nega-
tive and positive FIT results, as classified by the CRCSPs. The non-parametric Wilcoxon test
was used to compare the distribution of Hb levels in feces between TN and IC_test for negative
FIT results, compare CRC and FP for positive FIT results, and compare the CRC and IC_test
rate between women and men. The Spearman correlation test was applied to assess the impact
of age on the quantity of Hb in feces.
ROC curve analyses were carried out to detect the diagnostic accuracy of the FIT and the
cut-off value that maximizes sensitivity and specificity for CRC detection. The discriminatory
ability of the test was assessed by estimating the area under the curve (AUC). ROC curve analy-
ses were carried out for both the total sample and stratified by age and sex groups: women
aged 50–59, women aged 60–69, men aged 50–59, and men aged 60–69.
Finally, the results of the screening process were simulated for different cut-off values, in
particular for different optimal cut-off values for each age and sex group determined by means
of a ROC curve analysis (O1); for an optimal cut-off value for the total sample determined by
means of a ROC curve analysis (O2); and for cut-off values of 20, 25, 30, 35, and 45μg/g of
feces. The validity of the FIT was analyzed for each of these cut-off values by calculating the
sensitivity and specificity. Furthermore, the FP rate, IC_test rate, SC rate, and number of colo-
noscopies recommended were estimated for each of the cut-off values under study. The rates
at the different cut-off points were compared with the rates at the 20 μg/g cut-off using a Chi-
square analysis. The results were simulated both for the total sample and by age and sex group.
The statistical analyses were carried out using the statistical program R.
Fig 1. Study flow diagram. FIT, fecal immunochemical test; CRC, colorectal cancer; IC_test, test interval cancer;
IC_colono, colonoscopy interval cancer.
https://doi.org/10.1371/journal.pone.0254021.g001
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Results
Fig 2 shows the differences in fecal Hb concentration between CRC and FP, both of which are
positive FIT results (p<0.001). Differences in fecal Hb concentration between TN and IC_test,
both of which are negative FIT results, can also be seen. Hb levels were higher in men with
CRC (average = 166.2μg/g) than women with CRC (average = 140.2μg/g), P = 0.0186. No dif-
ferences were found between men and women with IC_test (p = 0.6914). A slight positive cor-
relation was found between age and fecal Hb concentration (Spearman correlation = 0.01,
p<0.001). This is not shown in the tables and figures.
The ROC curve analysis estimated an optimal cut-off value (O2) of 19.73μg/g of feces for
the total sample. This value determined the highest combination of sensitivity (90.2%) and
specificity (93.5%) for CRC diagnosis. The AUC was 95.4% (94.9%-95.9%), meaning that the
FIT is highly capable of correctly classifying patients with CRC and people that do not have
this cancer (Fig 3).
ROC curves were estimated by age and sex group in order to determine a specific optimal
cut-off value for CRC detection (O1), and this was set at 18.35μg/g for women aged 50–59; at
14.60μg/g for women aged 60–69; at 16.8μg/g for men aged 50–59; and at 19.92μg/g for men
aged 60–69. The AUC of all the estimated cut-off values was close to 100% and with confidence
intervals of between 93.7% and 97.1%. Therefore, the FIT is highly capable of correctly classify-
ing participants in all the age and sex groups analyzed (Fig 4).
Table 1 shows the simulations of general CRCSP results for different FIT cut-off values. A
very similar sensitivity would be obtained for the cut-off values O1, O2, and 20μg/g, and the
sensitivity falls from 90.11% to 79.5% if the cut-off value increases from 20 to 40μg/g. As com-
pared to the cut-off value of 20μg/g, with cut-off value O1 there is an increase in the FP
(0.54%) and SC (0.02‰) rates, and a decrease in the IC_test rate (0.03‰).
Fig 2. Distribution of fecal Hb levels according to the results of the screening process. FIT, fecal immunochemical
test; CRC, colorectal cancer; FP, false positive; TN, true negative; IC_test, test interval cancer.
https://doi.org/10.1371/journal.pone.0254021.g002
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CRCSP results by age and sex and for different cut-off values are shown in Fig 5. Cut-off
value O1 increased sensitivity and reduced specificity for women aged 50–59, women aged
60–69, and men aged 50–59 compared to all other cut-off values common to the entire
population.
Fig 6 shows that for cut-off value O1, a higher number of colonoscopies were required
(40,113), and the number of IC and SC varied very little in comparison to cut-off value O2 and
the regular cut-off value of 20μg/g.
Fig 3. ROC curve for the total sample, optimal cut-off value for CRC diagnosis. AUC, area under the curve.
https://doi.org/10.1371/journal.pone.0254021.g003
Fig 4. ROC curves by age and sex group, optimal cut-off values for CRC diagnosis. AUC, area under the curve.
https://doi.org/10.1371/journal.pone.0254021.g004
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CRC Sensitivity Specificity PPV FP IC_test SC
Yes No % 95%CI % 95%CI % 95%CI Rate % change vs. 20 Rate ‰ change vs. 20 Rate ‰ change vs. 20






6.99 0.54� 0.37 -0.03 3.63 0.02
Negative 204 505,190






6.48 0.03 0.39 -0.01 3.61 0
Negative 215 507,957














5.38 -1.07� 0.56 0.16� 3.45 -0.16
Negative 304 513,985






4.77 -1.68� 0.65 0.25� 3.35 -0.26�
Negative 357 517,283






4.31 -2.14� 0.73 0.33� 3.28 -0.33�
Negative 396 519,796






3.96 -2.49� 0.82 0.42� 3.18 -0.43�
Negative 448 521,726
CRC, Colorectal cancer; PPV, positive predictive value; FP, false positive; IC_test, test interval cancer; SC, screening cancer rates; O1, different optimal cut-off value for
each age and sex group, 18.35μg/g in women aged 50–59, 14.60μg/g in women aged 60–69, 16.78μg/g in men aged 50–59, and 19.91μg/g in men aged 60–69; O2, optimal
cut-off value of 19.73μg/g for the total sample; CI, confidence interval.
�p_valor<0.05.
https://doi.org/10.1371/journal.pone.0254021.t001
Fig 5. Sensitivity, specificity and rates with different FIT cut-off values for each age and sex group. FIT, fecal
immunochemical test CRC; FP, false positive; IC, interval cancer; SC, screening cancer; O1, different optimal cut-off
value for each age and sex group, 18.35μg/g in women aged 50–59, 14.60μg/g in women aged 60–69, 16.78μg/g in men
aged 50–59, and 19.91μg/g in men aged 60–69; O2, optimal cut-off value of 19.73μg/g.
https://doi.org/10.1371/journal.pone.0254021.g005
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Discussion
The optimal cut-off value that maximized FIT sensitivity and specificity is different for each
sex and age group. The use of an optimal cut-off value for each age and sex group enhances the
benefits in terms of increased CRC detection, but also increases the adverse effects of the
program.
The program results simulations are slightly different when using a cut-off value of 20μg/g
for the entire population or different cut-off values for each age and sex group. The use of dif-
ferent cut-off values multiplies program benefits, with an increase of the SC rate and a reduc-
tion of the IC_test rate. However, it also leads to an increase in the adverse effects of the
program, namely growth of the FP rate. The increase in the rate of FP leads to an increase in
the number of colonoscopies. In terms of the balance between program benefits and adverse
effects, the increase in the FP rate is larger than the increase in benefits. Therefore, the results
of this study show that the balance is still unclear.
Grobbee et al., 2017 concluded that changing the cut-off value for each sex could even out
the number of lesions not detected in screening between men and women [18]. The results of
CRCSPs using different cut-off values for each age and sex group have particularly significant
changes for men and women aged 50–59 and women aged 60–69: a decrease in the IC_test
rate and an increase in the SC and FP rate.
For men and women aged 50–59 and women aged 60–69, the optimal cut-off value is
slightly lower than the value used in conventional practice in European programs (20μg/g).
On the contrary, the optimal cut-off value for men aged 60–69 is the same as the value used in
conventional practice. Therefore, it would not be possible to decrease the IC_test rate in this
group with the cut-off points used in the study. This study has shown that the quantity of Hb
in feces is very low in IC_test, which suggests that it would be very difficult to decrease this
rate even if we lowered the FIT threshold. The results suggest that the amount of Hb in feces in
IC_test is undetectable when the test is performed. This could be due to the particular charac-
teristics of these cancers, for example, the fact that IC tends to be located in the proximal colon
or rectum [25].
Our study shows that men with CRC have a higher amount of Hb in feces than women
with CRC. These results are in line with other investigations showing that male CRCSP partici-
pants have higher fecal Hb concentrations that female CRCSP participants [17].
In terms of sensitivity, program results using a cut-off value of 20μg/g show that the FIT is
most sensitive in men aged 60–69, followed by women aged 50–59 and women aged 60–69. It
Fig 6. Number of colonoscopies recommended and proportion of IC and SC for different Hb cut-off values. IC,
interval cancer; SC, screening cancer; O1, different optimal cut-off value for each age and sex group, 18.35μg/g in
women aged 50–59, 14.60μg/g in women aged 60–69, 16.78μg/g in men aged 50–59, and 19.91μg/g in men aged 60–69;
O2, optimal cut-off value of 19.73μg/g for the total sample.
https://doi.org/10.1371/journal.pone.0254021.g006
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is least sensitive in men aged 50–59. A meta-analysis of scientific studies evaluating FIT sensi-
tivity by sex, found 3 studies that showed sensitivity is higher in men than women, as well as
another 3 studies evaluating FIT sensitivity by age showed sensitivity is higher in the 50–59 age
group than the 60–69 age group [26]. Our study, by combining age groups and sex, provides
more specific results on the changes in the sensitivity and specificity of the FIT than the usual
studies that classify by sex and age independently.
The use of different cut-off values for each age and sex group improves test sensitivity when
CRCSP results are evaluated for women aged 50–59, women aged 60–69, and men aged 50–59.
These results support the hypothesis of Alvarez-Urturi et al. (2016) that, to improve FIT per-
formance in CRCSP, cut-off values could be personalized by age and sex [22]. We have seen
that if we evaluate FIT performance in the entire population, the use of different cut-off values
does not lead to significant changes; namely, sensitivity generally remains at around 90% and
specificity at 93% for both criteria.
In contrast, the negative side of using different cut-off values for each age and sex group is
that the number of colonoscopies recommended increases, as well as the FP rate. FP in particu-
lar entails a negative effect on CRCSPs, as people may undergo unnecessary colonoscopy
(which increases the burden on healthcare workers) and suffer the stress of thinking they are
ill. Furthermore, colonoscopies carry certain risks, such as potential complications of the pro-
cedure (e.g. perforation or hemorrhage), and this is an adverse effect of CRCSPs. One study
associates men with a lower risk of FP [27]. Using estimated cut-off values for each age and sex
group would increase the FP rate in women and also in men aged 50–59, which could influ-
ence and maximize the differences between the sexes found in this adverse effect.
The diagnosis confirmation test, i.e., the colonoscopy, is carried out by the health system of
each region in Spain, in units that are not exclusive to CRCSPs. Colonoscopies resulting from
CRCSPs are a significant burden for the health system and the number of people referred for
this test must be well adjusted.
One limitation of the study is that it was not possible to analyze the sensitivity and specific-
ity for both CRC detection and adenomas, as we cannot count the number of adenomas not
detected by the FIT. Another limitation is that other variables that have been shown to be
related to FIT performance, such as tobacco use or personal history of FIT screening tests in
previous participations [19, 28] are not included in the study.
Following the recommendations of the European CRC screening guide [1], population-
based programs should be organizationally adapted according to the characteristics and
resources of each program. The results of this study can serve as the basis for making decisions
to modify the cut-off points. In any case, following the recommendations, information should
be provided to the population on both the benefits and the adverse effects of applying different
cut-off points.
Our investigation provides new evidence on how to use the FIT in a personalized manner
by age and sex. We have seen that using different cut-off values for different age and sex groups
generally provides different CRCSP results to the conventional cut-off value in terms of sensi-
tivity and specificity, and also increases the number of colonoscopies recommended in
CRCSPs (2,933 additional colonoscopies) and the FP rate (2,921 additional FPs). Both the ben-
efits and adverse effects of using different cut-off values for each age and sex group must be
considered when deciding the cut-off value to be used.
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23. Vanaclocha-Espi M, Ibáñez J, Molina-Barceló A, Pérez E, Nolasco A, Font R, et al. Factors influencing
participation in colorectal cancer screening programs in Spain. Prev Med. 2017 Dec; 105:190–196.
https://doi.org/10.1016/j.ypmed.2017.08.019 PMID: 28887191
24. Quality Assurance Guidelines for Colonoscopy. NHS Cancer Screening Programmes, Great Britain, y
National Health Service, 2011. ISBN: 978-1-84463-077-6
PLOS ONE Fecal immunochemical test cut-off values by age and sex
PLOS ONE | https://doi.org/10.1371/journal.pone.0254021 July 16, 2021 11 / 12
25. Blanks R, Burón Pust A, Alison R, He E, Barnes I, Patnick J, et al. Screen-detected and interval colorec-
tal cancers in England: Associations with lifestyle and other factors in women in a large UK prospective
cohort. Int J Cancer 2019; 145(3):728–734. https://doi.org/10.1002/ijc.32168 PMID: 30694563
26. Selby K, Levine EH, Doan C, Gies A, Brenner H, Quesenberry C, et al. Effect of Sex, Age, and Positivity
Threshold on Faecal Immunochemical Test Accuracy: A Systematic Review and Meta-analysis.
Gastroenterology 2019; 157(6):1494–1505. https://doi.org/10.1053/j.gastro.2019.08.023 PMID:
31472152
27. de Klerk CM, Vendrig LM, Bossuyt PM, Dekker E. Participant-Related Risk Factors for False-Positive
and False-Negative Faecal Immunochemical Test in Colorectal Cancer Screening: Systematic Review
and Meta-Analysis. Am J Gastroenterol 2018; 113(12):1778–1787. https://doi.org/10.1038/s41395-
018-0212-7 PMID: 30158713
28. Baldacchini F, Bucchi L, Giuliani O, Mancini S, Ravaioli A, Vattiato R, et al. Results of Compliant Partici-
pation in Five Rounds of Fecal Immunochemical Test Screening for Colorectal Cancer. Clin Gastroen-
terol Hepatol. 2020 Aug 20:S1542-3565(20)31147-2. https://doi.org/10.1016/j.cgh.2020.08.038 PMID:
32827723
PLOS ONE Fecal immunochemical test cut-off values by age and sex
PLOS ONE | https://doi.org/10.1371/journal.pone.0254021 July 16, 2021 12 / 12
